These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26808470)

  • 21. Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.
    Villa SR; Mishra RK; Zapater JL; Priyadarshini M; Gilchrist A; Mancebo H; Schiltz GE; Layden BT
    J Investig Med; 2017 Dec; 65(8):1116-1124. PubMed ID: 28784695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs.
    Hudson BD; Christiansen E; Tikhonova IG; Grundmann M; Kostenis E; Adams DR; Ulven T; Milligan G
    FASEB J; 2012 Dec; 26(12):4951-65. PubMed ID: 22919070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ.
    Ma L; Wang T; Shi M; Ye H
    Drug Des Devel Ther; 2016; 10():1807-15. PubMed ID: 27313447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
    Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemogenetics defines receptor-mediated functions of short chain free fatty acids.
    Bolognini D; Barki N; Butcher AJ; Hudson BD; Sergeev E; Molloy C; Moss CE; Bradley SJ; Le Gouill C; Bouvier M; Tobin AB; Milligan G
    Nat Chem Biol; 2019 May; 15(5):489-498. PubMed ID: 30992568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Specificity and Broad Multitarget Properties of Ligands for the Free Fatty Acid Receptors FFA3/GPR41 and FFA2/GPR43 and the Related Hydroxycarboxylic Acid Receptor HCA2/GPR109A.
    Bisenieks E; Vigante B; Petrovska R; Turovska B; Muhamadejev R; Soloduns V; Velena A; Pajuste K; Saso L; Klovins J; Duburs G; Mandrika I
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias.
    Bolognini D; Moss CE; Nilsson K; Petersson AU; Donnelly I; Sergeev E; König GM; Kostenis E; Kurowska-Stolarska M; Miller A; Dekker N; Tobin AB; Milligan G
    J Biol Chem; 2016 Sep; 291(36):18915-31. PubMed ID: 27385588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation.
    Le Poul E; Loison C; Struyf S; Springael JY; Lannoy V; Decobecq ME; Brezillon S; Dupriez V; Vassart G; Van Damme J; Parmentier M; Detheux M
    J Biol Chem; 2003 Jul; 278(28):25481-9. PubMed ID: 12711604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological properties of acid N-thiazolylamide FFA2 agonists.
    Brown AJ; Tsoulou C; Ward E; Gower E; Bhudia N; Chowdhury F; Dean TW; Faucher N; Gangar A; Dowell SJ
    Pharmacol Res Perspect; 2015 Jun; 3(3):e00141. PubMed ID: 26236484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.
    Koike T; Hoashi Y; Takai T; Nakayama M; Yukuhiro N; Ishikawa T; Hirai K; Uchikawa O
    J Med Chem; 2011 May; 54(9):3436-44. PubMed ID: 21473625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model.
    Hoveyda HR; Fraser GL; Zoute L; Dutheuil G; Schils D; Brantis C; Lapin A; Parcq J; Guitard S; Lenoir F; Bousmaqui ME; Rorive S; Hospied S; Blanc S; Bernard J; Ooms F; McNelis JC; Olefsky JM
    Bioorg Med Chem; 2018 Oct; 26(18):5169-5180. PubMed ID: 30253886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.
    Hansen AH; Sergeev E; Bolognini D; Sprenger RR; Ekberg JH; Ejsing CS; McKenzie CJ; Rexen Ulven E; Milligan G; Ulven T
    J Med Chem; 2018 Nov; 61(21):9534-9550. PubMed ID: 30247908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-chain fatty acid mitigates adenine-induced chronic kidney disease via FFA2 and FFA3 pathways.
    Mikami D; Kobayashi M; Uwada J; Yazawa T; Kamiyama K; Nishimori K; Nishikawa Y; Nishikawa S; Yokoi S; Kimura H; Kimura I; Taniguchi T; Iwano M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158666. PubMed ID: 32061840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FFA2 Activation Ameliorates 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis in Mice.
    Kang J; Im DS
    Biomol Ther (Seoul); 2020 May; 28(3):267-271. PubMed ID: 32279475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Signaling of free fatty acid receptors 2 and 3 differs in colonic mucosa following selective agonism or coagonism by luminal propionate.
    Tough IR; Forbes S; Cox HM
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13454. PubMed ID: 30136343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The short-chain fatty acid receptor, FFA2, contributes to gestational glucose homeostasis.
    Fuller M; Priyadarshini M; Gibbons SM; Angueira AR; Brodsky M; Hayes MG; Kovatcheva-Datchary P; Bäckhed F; Gilbert JA; Lowe WL; Layden BT
    Am J Physiol Endocrinol Metab; 2015 Nov; 309(10):E840-51. PubMed ID: 26394664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GPR43/FFA2: physiopathological relevance and therapeutic prospects.
    Bindels LB; Dewulf EM; Delzenne NM
    Trends Pharmacol Sci; 2013 Apr; 34(4):226-32. PubMed ID: 23489932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FFA2 and FFA3 in Metabolic Regulation.
    Tang C; Offermanns S
    Handb Exp Pharmacol; 2017; 236():205-220. PubMed ID: 27757760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.